New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 16, 2013
11:36 EDTGSK, RHHBY, BIIBAppeals court upholds ruling in patent suit between Glaxo, Biogen
Biogen Idec (BIIB) and Roche's (RHHBY) Genentech unit appealed a district court’s construction of a disputed claim term, “anti-CD20 antibody,” that narrowed the term in their patent dispute with GlaxoSmithKline (GSK). An appeals court concluded that "the district court did not err in finding a clear and unmistakable disclaimer" and affirmed the lower court's decision. Reference Link
News For BIIB;RHHBY;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 1, 2015
08:45 EDTRHHBYRoche has a conference call hosted by JPMorgan
Subscribe for More Information
07:46 EDTGSKFDA and the Parental Drug Association to co-host a conference
Subscribe for More Information
06:07 EDTGSKGSK enters development agreement, R&D collaboration with Propeller Health
Propeller Health announced a development agreement and R&D collaboration with GSK for its Ellipta inhaler, the pharmaceutical company's innovative, patented, dry powder inhaler. Under the terms of this non-exclusive agreement, the first between the two companies, Propeller Health will develop and manufacture a custom sensor for the Ellipta inhaler for use in certain GSK clinical studies in asthma and COPD.
November 30, 2015
10:05 EDTRHHBYRoche management to meet with JPMorgan
Subscribe for More Information
November 27, 2015
08:00 EDTGSKGlaxo has cut 40% of China sales reps in wake of scandal, Reuters reports
Subscribe for More Information
07:34 EDTGSKGlaxoSmithKline starts phase III study of sirukumab in Giant Cell Arteritis
Subscribe for More Information
November 25, 2015
11:29 EDTGSKStudy says Valeant, others exploding dermatology drug prices, WSJ reports
The JAMA Dermatology journal published a new study that found that retail prices of 19 dermatologic prescription drugs increased fivefold on average between 2009 and 2015, reported The Wall Street Journal. Targretin, marketed by Valeant (VRX), jumped to $30,320 this year from $15,708 last year and $1,687 in 2009, the study found, but "It's not just Valeant," said lead author Miranda Rosenberg. Prices for drugs made by GlaxoSmithKline (GSK) and Novartis (NVS) at least doubled or tripled over the same time frame, the report noted. Reference Link
November 24, 2015
11:16 EDTGSKAdaptimmune initiates Phase I/II trial of affinity enhanced T-cell therapy
Subscribe for More Information
05:34 EDTBIIBSobi, Biogen announce approval of Elocta in Europe
Subscribe for More Information
November 23, 2015
08:08 EDTGSKIdera Pharmaceuticals announces partnership with GSK
Idera Pharmaceuticals (IDRA) announced it has entered into an exclusive worldwide collaboration and license agreement with GSK (GSK) to research, develop and commercialize selected molecules from Idera's 3rd generation antisense platform for the treatment of selected targets in renal disease. Under the terms of the agreement, Idera is eligible to receive approximately $100M in development and regulatory milestone payments, including a $2.5M upfront payment. Additionally, Idera is eligible to receive royalties on all sales upon commercialization at varying rates up to five percent on annual net sales in excess of $500M.
November 22, 2015
15:14 EDTRHHBYExelixis confirms Phase 3 data on Cotellic with Zelboraf for melanoma
Subscribe for More Information
15:09 EDTRHHBYGenentech reports data on Cotellic with Zelboraf for treatment of melanoma
Genentech, a member of the Roche Group, announced data from the pivotal coBRIM study, showing that Cotellic, or cobimetinib, in combination with Zelboraf, or vemurafenib, helped people with BRAF V600E and V600K mutation-positive unresectable or metastatic melanoma live "significantly longer" than with Zelboraf alone, according to the company. Cotellic plus Zelboraf reduced the risk of death by 30% compared to Zelboraf alone and helped people live a median of nearly two years, with 74.5% of BRAF V600 patients alive at one year and 48.3% alive at two years. Ongoing study monitoring did not identify any new safety signals. The company noted that an approval decision on Cotellic from the European Commission is expected before year end.
November 20, 2015
07:17 EDTBIIBBiogen says Benepali receives 'positive' opinion from CHMP
Subscribe for More Information
November 18, 2015
08:28 EDTRHHBYLeerink to hold a bus tour
Subscribe for More Information
08:11 EDTGSK, RHHBYIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use